7 ways digital health is transforming patient care

Digital tools are changing the way patients think about healthcare and how they want to access care, according to a survey conducted by Aetna.

The Health Ambitions Study included responses from 1,000 consumers, 200 primary care physicians and 200 specialists. The survey aimed to provide insight into how patients and providers view technological advances in healthcare and what could be improved.

Findings included:

  1. 37 percent of consumers said being able to communicate through email, text or a patient portal would make them more likely to connect with physicians.
  2. 32 percent of consumers said virtual office visits would make them more likely to communicate with physicians.
  3. 40 percent of people between 18 and 34 are currently using a computer or electronic diary to track health.
  4. 30 percent were using a wearable tracker to collect information about their personal health.
  5. Doctors with 15 years or fewer years of experience are more inclined to use digital tools—23 percent reported they would use digital messaging, 22 percent would use telehealth and 18 percent would use virtual office visits.
  6. 43 percent of consumers between 18 and 34 said apps would help them make regular progress toward goals.
  7. 81 percent said they would use a confidential website or app to track health information.
""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.